WGS · Genedx Holdings Corp. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $102.25M | - | $116.74M | $102.69M | $87.11M | - | $76.87M | $70.51M | $62.42M | - |
| Cost of Revenue | $34.04M | - | $32.22M | $31.79M | $28.64M | - | $29.05M | $27.56M | $25.01M | - |
| Gross Profit | $68.21M | - | $84.53M | $70.90M | $58.48M | - | $47.83M | $42.95M | $37.41M | - |
| R&D | $19.80M | - | $19.83M | $15.08M | $12.58M | - | $11.66M | $10.90M | $11.57M | - |
| SG&A | $50.45M | - | $44.44M | $27.41M | $32.13M | - | $26.14M | $25.17M | $22.45M | - |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - | - |
| D&A | $2.70M | - | $2.37M | $2.29M | $2.17M | - | $2.42M | $1.71M | $1.74M | - |
| Operating Income | ($57.47M) | - | ($3.25M) | $8.96M | ($4.55M) | - | ($7.78M) | ($10.58M) | ($13.66M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $897.0K | - | $247.0K | ($246.0K) | $447.0K | - | ($47.0K) | ($190.0K) | ($82.0K) | - |
| Net Income | ($63.32M) | - | ($7.63M) | $10.81M | ($6.53M) | - | ($8.31M) | ($29.17M) | ($20.24M) | - |
| EPS - Basic | ($2.16) | - | ($0.27) | $0.38 | ($0.23) | - | ($0.31) | ($1.10) | ($0.78) | - |
| EPS - Diluted | ($2.16) | - | ($0.27) | $0.36 | ($0.23) | - | ($0.31) | ($1.10) | ($0.78) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $93.92M | $105.00M | $95.97M | $74.12M | $99.70M | $85.21M | $57.89M | $56.08M | $83.67M | $99.68M |
| Accounts Receivable | $76.93M | $74.37M | $60.94M | $48.03M | $45.98M | - | - | - | - | - |
| Inventory | $12.24M | $13.95M | $10.57M | $11.93M | $12.66M | $10.65M | $10.77M | $10.32M | $11.62M | $8.78M |
| Accounts Payable | $11.17M | $2.46M | $2.63M | $3.52M | $15.86M | $7.95M | $9.02M | $8.13M | $9.48M | $10.24M |
| Current Assets | $270.63M | $268.29M | $237.58M | $204.84M | $225.82M | $197.97M | $186.01M | $162.17M | $163.42M | $182.34M |
| Total Assets | $506.30M | $523.71M | $493.90M | $463.86M | $446.43M | $419.38M | $408.84M | $389.10M | $394.53M | $418.76M |
| Current Liabilities | $87.64M | $108.91M | $87.62M | $71.41M | $69.54M | $54.82M | $77.34M | $68.27M | $50.73M | $58.82M |
| Long-term Debt | $96.73M | $48.18M | $51.58M | $51.68M | $51.79M | $51.91M | $52.03M | $52.16M | $52.29M | $52.69M |
| Total Liabilities | $252.18M | $215.53M | $201.64M | $186.73M | $189.03M | $174.13M | $204.34M | $195.06M | $187.31M | $190.74M |
| Stockholders' Equity | $254.12M | $308.18M | $292.26M | $277.13M | $257.40M | $245.25M | $204.50M | $194.04M | $207.22M | $228.02M |
| Retained Earnings | ($1.44B) | ($1.37B) | ($1.36B) | ($1.35B) | ($1.36B) | ($1.35B) | ($1.36B) | ($1.35B) | ($1.32B) | ($1.30B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($32.41M) | - | - | - | $10.18M | - | - | - | ($16.41M) | - |
| Investing Cash Flow | ($17.25M) | - | - | - | ($9.41M) | - | - | - | $843.0K | - |
| Financing Cash Flow | $38.59M | - | - | - | $13.72M | - | - | - | ($438.0K) | - |
| CapEx | $6.45M | - | - | - | $6.13M | - | - | - | $443.0K | - |
| Free Cash Flow | ($38.86M) | - | - | - | $4.05M | - | - | - | ($16.86M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 66.7% | - | 72.4% | 69.0% | 67.1% | - | 62.2% | 60.9% | 59.9% | - |
| Operating margin | -56.2% | - | -2.8% | 8.7% | -5.2% | - | -10.1% | -15.0% | -21.9% | - |
| EBITDA margin | -53.6% | - | -0.8% | 11.0% | -2.7% | - | -7.0% | -12.6% | -19.1% | - |
| Net margin | -61.9% | - | -6.5% | 10.5% | -7.5% | - | -10.8% | -41.4% | -32.4% | - |
| Free cash flow margin | -38.0% | - | - | - | 4.7% | - | - | - | -27.0% | - |
| FCF / Net income | 0.61 | - | - | - | -0.62 | - | - | - | 0.83 | - |
| R&D / Revenue | 19.4% | - | 17.0% | 14.7% | 14.4% | - | 15.2% | 15.5% | 18.5% | - |
| SG&A / Revenue | 49.3% | - | 38.1% | 26.7% | 36.9% | - | 34.0% | 35.7% | 36.0% | - |
| Effective tax rate | - | - | - | -2.3% | - | - | - | - | - | - |
| Return on assets | -12.5% | - | -1.5% | 2.3% | -1.5% | - | -2.0% | -7.5% | -5.1% | - |
| Return on equity | -24.9% | - | -2.6% | 3.9% | -2.5% | - | -4.1% | -15.0% | -9.8% | - |
| Return on invested capital | -12.9% | - | -0.7% | 2.7% | -1.2% | - | -2.4% | -3.4% | -4.2% | - |
| Liquidity | ||||||||||
| Current ratio | 3.09 | 2.46 | 2.71 | 2.87 | 3.25 | 3.61 | 2.41 | 2.38 | 3.22 | 3.10 |
| Quick ratio | 2.95 | 2.34 | 2.59 | 2.70 | 3.07 | 3.42 | 2.27 | 2.22 | 2.99 | 2.95 |
| Cash ratio | 1.07 | 0.96 | 1.10 | 1.04 | 1.43 | 1.55 | 0.75 | 0.82 | 1.65 | 1.69 |
| Leverage | ||||||||||
| Debt / Equity | 0.38 | 0.16 | 0.18 | 0.19 | 0.20 | 0.21 | 0.25 | 0.27 | 0.25 | 0.23 |
| Debt / Assets | 0.19 | 0.09 | 0.10 | 0.11 | 0.12 | 0.12 | 0.13 | 0.13 | 0.13 | 0.13 |
| Debt / EBITDA | - | - | - | 4.60 | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.99 | 1.70 | 1.69 | 1.67 | 1.73 | 1.71 | 2.00 | 2.01 | 1.90 | 1.84 |
| Liabilities / Assets | 0.50 | 0.41 | 0.41 | 0.40 | 0.42 | 0.42 | 0.50 | 0.50 | 0.47 | 0.46 |
| Efficiency | ||||||||||
| Asset turnover | 0.20 | - | 0.24 | 0.22 | 0.20 | - | 0.19 | 0.18 | 0.16 | - |
| Inventory turnover | 2.78 | - | 3.05 | 2.66 | 2.26 | - | 2.70 | 2.67 | 2.15 | - |
| Days sales outstanding | 275d | - | 191d | 171d | 193d | - | - | - | - | - |
| Days inventory outstanding | 131d | - | 120d | 137d | 161d | - | 135d | 137d | 170d | - |
| Days payable outstanding | 120d | - | 30d | 40d | 202d | - | 113d | 108d | 138d | - |
| Cash conversion cycle | 286d | - | 280d | 267d | 152d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 256.4x | - | - | - | - | - | - |
| P / B | 7.4x | - | 10.6x | 9.9x | 9.7x | - | 5.6x | 3.6x | 1.1x | - |
| P / S | 18.4x | - | 26.6x | 26.7x | 28.6x | - | 15.0x | 9.9x | 3.8x | - |
| EV / EBITDA | - | - | - | 242.2x | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 17.4% | - | 51.9% | 45.6% | 39.6% | - | 44.2% | 44.8% | 44.7% | - |
| Revenue CAGR (3y) | 33.3% | - | 11.9% | 41.6% | 17.3% | - | 25.8% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 16.6% | - | 76.7% | 65.1% | 56.3% | - | 89.4% | 129.0% | 145.5% | - |
| Operating income growth (YoY) | -1162.8% | - | 58.2% | - | 66.7% | - | 81.9% | 79.5% | 77.4% | - |
| Net income growth (YoY) | -869.8% | - | 8.1% | - | 67.7% | - | 80.3% | 37.6% | 66.8% | - |
| EPS growth (YoY) | -839.1% | - | 12.9% | - | 70.5% | - | 81.1% | 40.2% | 74.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | 69.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -1.3% | 25.7% | 42.9% | 42.8% | 24.2% | 7.6% | -19.6% | -34.5% | -36.9% | -10.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$427.54M totalGene Dx$423.09M · 99.0%
All Other Segments$4.45M · 1.0%
Product / service
$843.18M totalDiagnostic Test$416.67M · 49.4%
Diagnostic Test Third Party Insurance$345.24M · 40.9%
Diagnostic Test Institutional Customers$69.05M · 8.2%
Product And Service Other$10.87M · 1.3%
Diagnostic Test Self Pay$1.36M · 0.2%
Peer comparison
Same SIC group: Services-Health Services
Comparing GeneDx Holdings Corp. against the 5 most active filers in the same SIC group.